Biaryl kinase inhibitors

Patent metadata

Field	Value
Publication number	US-10351563-B2
Application number	US-201816168533-A
Country	US
Kind code	B2
Filing date	Oct 23, 2018
Priority date	Apr 2, 2014
Publication date	Jul 16, 2019
Grant date	Jul 16, 2019

Abstract

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

First claim

The invention claimed is:

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Bristol Myers Squibb Co

Inventors

• Luo Guanglin

Classifications

• C07D239/26

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• C07D237/08

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• C07D401/14 Primary

  containing three or more hetero rings · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D213/30

  Oxygen atoms · CPC title